Efficacy and Safety of ICD Remote Monitored Exercise Testing to Improve Heart Failure Outcomes: REMOTE HF-ACTION

Heart Failure Clinical Trial

— x  

Official title:

Efficacy and Safety of ICD Remote Monitored Exercise Testing to Improve Heart Failure Outcomes: REMOTE HF-ACTION (Pilot Randomized Controlled Trial)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04629066
• Other study ID #: Pro00107053
• Status: Completed
• Phase: N/A
• Start date: April 27, 2021
• Est. completion date: March 15, 2022

Study information

• Verified date: September 2023
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This single center randomized controlled trial will involve 50 medically stable outpatients with HF, reduced ejection fraction, and previously implanted ICD or CRT-D devices followed longitudinally on the Abbott Medical Merlin remote patient monitoring network. Patients will be randomized in a 1:1 fashion to usual care plus a remotely administered home based weekly prescription for aerobic exercise (intervention) or usual care alone (control). Usual care will include regularly scheduled visits with the clinical heart failure care team and medical therapy as prescribed by that team. The exercise prescription will be created by an exercise physiologist after incorporating remotely collected data from a patient directed smartphone app assessing HF symptom severity, vital signs, weight, and blood sugar, implantable device measures of physical activity, heart rate, heart failure volume status and heart rhythm, and Fitbit measures of physical activity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: March 15, 2022
• Est. primary completion date: March 15, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients have a MERLIN patient registry record for an ICD or CRT-D implantation between 01/01/2010-12/31/2020

• Age > 18 years

• Left ventricular ejection fraction < 50% by echocardiogram, nuclear cardiology scan, cardiac magnetic resonance imaging, or invasive left ventriculography within the past 12 months.

• Ongoing NYHA class II, III, or IV HF symptoms by questionnaire

• Ongoing use of beta-blocker and ACE-inhibitor or angiotensin receptor blocker or willingness to start them- assessed by Duke Epic EMR screening.

• Life expectancy > 12 months

• To allow for a post-surgical adjustment period, patients must be >30 days out from device implantation

Exclusion Criteria:

• Prior participation in CR- by patient questionnaire

• Unwillingness to sign informed consent form

• Currently performing > 240 minutes of device detected daily PA- by ICD/CRTD remotely collected data.

• Lack of a smartphone or unwillingness to use an App or Fitbit device

• Prior left ventricular assist device (LVAD) implantation or heart transplantation

• ICD tachyarrhythmia therapies programmed off

• Inherited arrhythmia condition with contraindication to exercise (eg Lamin A mutation or ARVC)

• No transmissions through Merlin.net in past 12 months

Related Conditions & MeSH terms

• Heart Failure

Intervention

Behavioral:
• Remote Cardiac Rehabilitation (CR)
Patients randomized to remote CR will be asked to use an app for cardiac rehabilitation a minimum of 3 times a week. Patients will be given an exercise prescription provided by a certified exercise physiologist. The exercise prescription will change each week based on refreshed data from the prior week. Instructional videos for each exercise are provided in the app. Patients will not be told to perform the exercise at a particular time. Instead they will be asked to complete a certain amount of exercise per week at whatever time is convenient for them. Patients randomized to remote CR will also receive App based reminders to take their medications, resources to guide healthy eating habits, and other behavioral health advice as is done as standard of care in both remote based and clinic based CR.

Locations

Country	Name	City	State
United States	Duke University Medical Center	Durham	North Carolina

Sponsors (3)

Lead Sponsor	Collaborator
Duke University	Medical Device Innovation Consortium (MDIC), National Evaluation System for health Technology Coordinating Center (NESTcc)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Abbott Implantable Cardioverter-defibrillator (ICD) or Cardiac Resynchronization Therapy Defibrillator (CRT-D) Device Measured Daily Physical Activity (PA)	Reported in minutes of PA per day.	12 weeks after randomization
Secondary	Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Heart Failure (HF) Symptoms Severity Score	The KCCQ has a range of 0 to 100, where a higher score indicates a more favorable health status.	Baseline to 12 weeks
Secondary	Number of Heart Failure Hospitalization, Fracture, Myocardial Infarction, Serious Adverse Arrhythmia, and ICD Therapy Combination Events		Cumulative during 12 weeks of intervention
Secondary	Kansas City Cardiomyopathy Questionnaire (KCCQ) Heart Failure (HF) Symptom Severity Score	The KCCQ has a range of 0 to 100, where a higher score indicates a more favorable health status.	12 weeks after randomization